In a study of a population cohort in South Africa, HIV patients on antiretrovirals had nearly full recovery of employment

Health Affairs

Volumn 31, Issue 7, 2012, Pages 1459-1469

  Bor, Jacob ^a   Tanser, Frank ^b   Newell, Marie Louise ^c   Bärnighausen, Till ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL STUDY; CONTROLLED STUDY; CONVALESCENCE; DECISION MAKING; EMPLOYMENT; FEMALE; HEALTH PROGRAM; HELP SEEKING BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POPULATION; RURAL AREA; SOCIOECONOMICS; SOUTH AFRICA; TREATMENT OUTCOME; UNEMPLOYMENT;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; EMPLOYMENT; FEMALE; HIV INFECTIONS; HUMANS; INTERNATIONAL COOPERATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SICK LEAVE; SOCIOECONOMIC FACTORS; SOUTH AFRICA; YOUNG ADULT;

EID: 84866297254     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2012.0407     Document Type: Article

References (27)

1. Egger M, May M, Chêne G, Phillips AN, Lederberger B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002; 360:119-29.
2. Beard J, Feeley F, Rosen S. Economic and quality of life outcomes of antiretroviral therapy for HIV/AIDS in developing countries: a systematic literature review. AIDS Care. 2009; 21:1343-56.
3. Zaidi J, Grapsa E, Tanser F, Newell ML, Bärnighausen T. HIV prevalence trends after scale-up of antiretroviral treatment. Unpublished paper, 2012.
4. Rosen S, Ketlhapile M, Sanne I, DeSilva MB. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008;22:S131-9.
5. Rosen S, Larson B, Brennan A, Long L, Fox M, Mongwenyana C, et al. Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010;5:e12731.
6. Thirumurthy H, Zivin JG, Goldstein M. The economic impact of AIDS treatment. J Hum Resour. 2008;43: 511-52.
7. Thirumurthy H, Jafri A, Srinivas G, Arumugam V, Saravanan RM, Angappan SK, et al. Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study. AIDS. 2011;25:239-46.
8. Coetzee C. The impact of highly active antiretroviral treatment (HAART) on employment in Khayelitsha. S Afr J Econ. 2008;76: S75-85.
9. Larson BA, Fox MP, Rosen S, Bii M, Sigei C, Shaffer D, et al. Do the socioeconomic impacts of antiretroviral therapy vary by gender? A longitudinal study of Kenyan agricultural worker employment outcomes. BMC Public Health. 2009; 9:240.
10. Habyarimana J, Mbakile B, Pop-Eleches C. The impact of HIV/AIDS and ARV treatment on worker absenteeism. J Hum Resour. 2010;45: 809-39.
11. Tanser F, Hosegood V, Bärnighausen T, Herbst K, Nyirenda M, Muhwava W, et al. Cohort profile: Africa Centre Demographic Information System (ACDIS) and population-based HIV survey. Int J Epidemiol. 2008;37:956-62.
12. To access the Appendix, click on the Appendix link in the box to the right of the article online
13. Houlihan CF, Bland RM, Mutevedzi PC, Lessells RJ, Ndirangu J, Thulare H, et al. Cohort profile: Hlabisa HIV Treatment and Care Programme. Int J Epidemiol. 2010;40:318-26.
14. 3. Department of Health, Republic of South Africa. The South African antiretroviral treatment guidelines. Pretoria: The Department; 2010.
15. ForInterim proposal for a WHO Staging System for HIV Infection and Disease. Wkly Epidemiol Rec. 1990;65(29):221-4.
16. Bertrand M, Duflo E, Mullainathan S. How much should we trust differences-in-differences estimates? Q J Econ. 2004;119(1):249-75.
17. Baker JV, Peng G, Rapkin J, Abrams DI, Silverberg MJ, MacArthur RD, et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection. AIDS. 2008;22:841-8.
18. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr. 2007; 46:72-7.
19. Barnett T, Whiteside A. AIDS in the twenty-first century: disease and globalization. New York (NY): Palgrave Macmillan; 2002.
20. Leach-Kemon K, Chou DP, Schneider MT, Tardif A, Dieleman JL, Brooks BPC, et al. The global financial crisis has led to a slowdown in growth of funding to improve health in many developing countries. Health Aff (Millwood). 2012; 31:228-35.
21. Resch S, Korenromp E, Stover J, Blakley M, Krubiner C, Thorien K, et al. Economic returns to investment in AIDS treatment in low and middle income countries. PLoS One. 2011;6:e25310.
22. Over M. Achieving an AIDS transition: preventing infections to sustain treatment. Washington (DC): Center for Global Development; 2011.
23. Bor J, Bärnighausen T, Newell C, Tanser F, Newell ML. Social exposure to an antiretroviral treatment programme in rural KwaZulu-Natal. Trop Med Int Health. 2011;16: 988-94.
24. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365:493-505.
25. Muula AS, Ngulube TJ, Siziya S, Makupe CM, Umar E, Prozesky HW, et al. Gender distribution of adult patients on highly active antiretroviral therapy (HAART) in Southern Africa: a systematic review. BMC Public Health. 2007;7:63.
26. Bärnighausen T, Tanser F, Dabis F, Newell ML. Interventions to improve the performance of HIV health systems for treatment-as-prevention in sub-Saharan Africa: the experimental evidence. Curr Opin HIV AIDS. 2012;7:140-50.
27. Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377: 2031-41.